Loading…

The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance

Inflammation at the level of the β cell appears to be involved in progressive β‐cell dysfunction in type 2 diabetes. We assessed the effect of blocking interleukin‐1 (IL‐1) by anakinra [recombinant human interleukin‐1 receptor antagonist (IL‐1Ra)] on β‐cell function. Sixteen participants with impair...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes, obesity & metabolism obesity & metabolism, 2014-12, Vol.16 (12), p.1269-1273
Main Authors: van Poppel, P. C. M., van Asseldonk, E. J. P., Holst, J. J., Vilsbøll, T., Netea, M. G., Tack, C. J.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c5227-7f7fff23e344df86c01dfc0a5782ff6b1c8c9e28b425270994411e2ab08c48fa3
cites cdi_FETCH-LOGICAL-c5227-7f7fff23e344df86c01dfc0a5782ff6b1c8c9e28b425270994411e2ab08c48fa3
container_end_page 1273
container_issue 12
container_start_page 1269
container_title Diabetes, obesity & metabolism
container_volume 16
creator van Poppel, P. C. M.
van Asseldonk, E. J. P.
Holst, J. J.
Vilsbøll, T.
Netea, M. G.
Tack, C. J.
description Inflammation at the level of the β cell appears to be involved in progressive β‐cell dysfunction in type 2 diabetes. We assessed the effect of blocking interleukin‐1 (IL‐1) by anakinra [recombinant human interleukin‐1 receptor antagonist (IL‐1Ra)] on β‐cell function. Sixteen participants with impaired glucose tolerance were treated with 150 mg anakinra daily for 4 weeks in a double blind, randomized, placebo‐controlled cross‐over study with a wash‐out period of 4 weeks. At the end of each treatment period, oral glucose tolerance tests (OGTTs) and hyperglycaemic clamps were performed. First‐phase insulin secretion improved after anakinra treatment compared with placebo, 148 ± 20 versus 123 ± 14 mU/l, respectively (p = 0.03), and the insulinogenic index was higher after anakinra treatment. These results support the concept of involvement of IL‐1β in the (progressive) decrease of insulin secretion capacity associated with type 2 diabetes.
doi_str_mv 10.1111/dom.12357
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1654684713</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1622596927</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5227-7f7fff23e344df86c01dfc0a5782ff6b1c8c9e28b425270994411e2ab08c48fa3</originalsourceid><addsrcrecordid>eNqNkstu1DAUhiMEohdY8AIoEhu6SOtr7CzRFAak0kpQBDvLcY5nPM3EU9uh7aPwtjidThdIILzxsf2dTzryXxSvMDrGeZ10fn2MCeXiSbGPWU0rTEn99L4mlWwQ2SsOYlwhhBiV4nmxRziiDcVyv_h1uYTSDQlCD-OVGypcBjCwST6Uekh64QcXUy51fgy6dOtN8D8hltaFmKrNUsepP469G8oIJkByfsh8t7v1CxicyacObssJGtsVmBTLG5eWk0-7AF256Efjsyv5HoIeDLwonlndR3j5sB8W3z68v5x9rM4u5p9m784qwwkRlbDCWksoUMY6K2uDcGcN0lxIYm3dYiNNA0S2jHAiUNMwhjEQ3SJpmLSaHhZvt9482PUIMam1iwb6Xg_gx6hwzVktmcD0P1BCeFM3RGT0zR_oyo9hyIMoinjDOKrFP6nJhQjiAmXqaEuZ4GMMYNUmuLUOdwojNQVA5QCo-wBk9vWDcWzX0D2Sux_PwMkWuHE93P3dpE4vPu-U1bYjBwFuHzt0uFK1oIKr7-dzNZ99nZ2f_viiGP0NUBTLMw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1622020570</pqid></control><display><type>article</type><title>The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>van Poppel, P. C. M. ; van Asseldonk, E. J. P. ; Holst, J. J. ; Vilsbøll, T. ; Netea, M. G. ; Tack, C. J.</creator><creatorcontrib>van Poppel, P. C. M. ; van Asseldonk, E. J. P. ; Holst, J. J. ; Vilsbøll, T. ; Netea, M. G. ; Tack, C. J.</creatorcontrib><description>Inflammation at the level of the β cell appears to be involved in progressive β‐cell dysfunction in type 2 diabetes. We assessed the effect of blocking interleukin‐1 (IL‐1) by anakinra [recombinant human interleukin‐1 receptor antagonist (IL‐1Ra)] on β‐cell function. Sixteen participants with impaired glucose tolerance were treated with 150 mg anakinra daily for 4 weeks in a double blind, randomized, placebo‐controlled cross‐over study with a wash‐out period of 4 weeks. At the end of each treatment period, oral glucose tolerance tests (OGTTs) and hyperglycaemic clamps were performed. First‐phase insulin secretion improved after anakinra treatment compared with placebo, 148 ± 20 versus 123 ± 14 mU/l, respectively (p = 0.03), and the insulinogenic index was higher after anakinra treatment. These results support the concept of involvement of IL‐1β in the (progressive) decrease of insulin secretion capacity associated with type 2 diabetes.</description><identifier>ISSN: 1462-8902</identifier><identifier>EISSN: 1463-1326</identifier><identifier>DOI: 10.1111/dom.12357</identifier><identifier>PMID: 25039318</identifier><identifier>CODEN: DOMEF6</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Beta cells ; Blood Glucose - drug effects ; Cross-Over Studies ; Diabetes ; diabetes mellitus ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - drug therapy ; Double-Blind Method ; drug mechanism ; experimental pharmacology ; Female ; Glucose Intolerance - blood ; Glucose Intolerance - drug therapy ; Glucose tolerance ; Glucose Tolerance Test ; Humans ; Hypoglycemic Agents - administration &amp; dosage ; Hypoglycemic Agents - therapeutic use ; Insulin - metabolism ; Insulin Secretion ; Insulin-Secreting Cells - drug effects ; Insulin-Secreting Cells - metabolism ; Interleukin 1 receptor antagonist ; Interleukin 1 Receptor Antagonist Protein - administration &amp; dosage ; Interleukin 1 Receptor Antagonist Protein - therapeutic use ; Male ; Middle Aged ; Placebos ; Receptors, Interleukin-1 - antagonists &amp; inhibitors ; Treatment Outcome ; type 2 diabetes ; β cell</subject><ispartof>Diabetes, obesity &amp; metabolism, 2014-12, Vol.16 (12), p.1269-1273</ispartof><rights>2014 John Wiley &amp; Sons Ltd</rights><rights>2014 John Wiley &amp; Sons Ltd.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5227-7f7fff23e344df86c01dfc0a5782ff6b1c8c9e28b425270994411e2ab08c48fa3</citedby><cites>FETCH-LOGICAL-c5227-7f7fff23e344df86c01dfc0a5782ff6b1c8c9e28b425270994411e2ab08c48fa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25039318$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Poppel, P. C. M.</creatorcontrib><creatorcontrib>van Asseldonk, E. J. P.</creatorcontrib><creatorcontrib>Holst, J. J.</creatorcontrib><creatorcontrib>Vilsbøll, T.</creatorcontrib><creatorcontrib>Netea, M. G.</creatorcontrib><creatorcontrib>Tack, C. J.</creatorcontrib><title>The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance</title><title>Diabetes, obesity &amp; metabolism</title><addtitle>Diabetes Obes Metab</addtitle><description>Inflammation at the level of the β cell appears to be involved in progressive β‐cell dysfunction in type 2 diabetes. We assessed the effect of blocking interleukin‐1 (IL‐1) by anakinra [recombinant human interleukin‐1 receptor antagonist (IL‐1Ra)] on β‐cell function. Sixteen participants with impaired glucose tolerance were treated with 150 mg anakinra daily for 4 weeks in a double blind, randomized, placebo‐controlled cross‐over study with a wash‐out period of 4 weeks. At the end of each treatment period, oral glucose tolerance tests (OGTTs) and hyperglycaemic clamps were performed. First‐phase insulin secretion improved after anakinra treatment compared with placebo, 148 ± 20 versus 123 ± 14 mU/l, respectively (p = 0.03), and the insulinogenic index was higher after anakinra treatment. These results support the concept of involvement of IL‐1β in the (progressive) decrease of insulin secretion capacity associated with type 2 diabetes.</description><subject>Beta cells</subject><subject>Blood Glucose - drug effects</subject><subject>Cross-Over Studies</subject><subject>Diabetes</subject><subject>diabetes mellitus</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Double-Blind Method</subject><subject>drug mechanism</subject><subject>experimental pharmacology</subject><subject>Female</subject><subject>Glucose Intolerance - blood</subject><subject>Glucose Intolerance - drug therapy</subject><subject>Glucose tolerance</subject><subject>Glucose Tolerance Test</subject><subject>Humans</subject><subject>Hypoglycemic Agents - administration &amp; dosage</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin - metabolism</subject><subject>Insulin Secretion</subject><subject>Insulin-Secreting Cells - drug effects</subject><subject>Insulin-Secreting Cells - metabolism</subject><subject>Interleukin 1 receptor antagonist</subject><subject>Interleukin 1 Receptor Antagonist Protein - administration &amp; dosage</subject><subject>Interleukin 1 Receptor Antagonist Protein - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Placebos</subject><subject>Receptors, Interleukin-1 - antagonists &amp; inhibitors</subject><subject>Treatment Outcome</subject><subject>type 2 diabetes</subject><subject>β cell</subject><issn>1462-8902</issn><issn>1463-1326</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNqNkstu1DAUhiMEohdY8AIoEhu6SOtr7CzRFAak0kpQBDvLcY5nPM3EU9uh7aPwtjidThdIILzxsf2dTzryXxSvMDrGeZ10fn2MCeXiSbGPWU0rTEn99L4mlWwQ2SsOYlwhhBiV4nmxRziiDcVyv_h1uYTSDQlCD-OVGypcBjCwST6Uekh64QcXUy51fgy6dOtN8D8hltaFmKrNUsepP469G8oIJkByfsh8t7v1CxicyacObssJGtsVmBTLG5eWk0-7AF256Efjsyv5HoIeDLwonlndR3j5sB8W3z68v5x9rM4u5p9m784qwwkRlbDCWksoUMY6K2uDcGcN0lxIYm3dYiNNA0S2jHAiUNMwhjEQ3SJpmLSaHhZvt9482PUIMam1iwb6Xg_gx6hwzVktmcD0P1BCeFM3RGT0zR_oyo9hyIMoinjDOKrFP6nJhQjiAmXqaEuZ4GMMYNUmuLUOdwojNQVA5QCo-wBk9vWDcWzX0D2Sux_PwMkWuHE93P3dpE4vPu-U1bYjBwFuHzt0uFK1oIKr7-dzNZ99nZ2f_viiGP0NUBTLMw</recordid><startdate>201412</startdate><enddate>201412</enddate><creator>van Poppel, P. C. M.</creator><creator>van Asseldonk, E. J. P.</creator><creator>Holst, J. J.</creator><creator>Vilsbøll, T.</creator><creator>Netea, M. G.</creator><creator>Tack, C. J.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201412</creationdate><title>The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance</title><author>van Poppel, P. C. M. ; van Asseldonk, E. J. P. ; Holst, J. J. ; Vilsbøll, T. ; Netea, M. G. ; Tack, C. J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5227-7f7fff23e344df86c01dfc0a5782ff6b1c8c9e28b425270994411e2ab08c48fa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Beta cells</topic><topic>Blood Glucose - drug effects</topic><topic>Cross-Over Studies</topic><topic>Diabetes</topic><topic>diabetes mellitus</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Double-Blind Method</topic><topic>drug mechanism</topic><topic>experimental pharmacology</topic><topic>Female</topic><topic>Glucose Intolerance - blood</topic><topic>Glucose Intolerance - drug therapy</topic><topic>Glucose tolerance</topic><topic>Glucose Tolerance Test</topic><topic>Humans</topic><topic>Hypoglycemic Agents - administration &amp; dosage</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin - metabolism</topic><topic>Insulin Secretion</topic><topic>Insulin-Secreting Cells - drug effects</topic><topic>Insulin-Secreting Cells - metabolism</topic><topic>Interleukin 1 receptor antagonist</topic><topic>Interleukin 1 Receptor Antagonist Protein - administration &amp; dosage</topic><topic>Interleukin 1 Receptor Antagonist Protein - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Placebos</topic><topic>Receptors, Interleukin-1 - antagonists &amp; inhibitors</topic><topic>Treatment Outcome</topic><topic>type 2 diabetes</topic><topic>β cell</topic><toplevel>online_resources</toplevel><creatorcontrib>van Poppel, P. C. M.</creatorcontrib><creatorcontrib>van Asseldonk, E. J. P.</creatorcontrib><creatorcontrib>Holst, J. J.</creatorcontrib><creatorcontrib>Vilsbøll, T.</creatorcontrib><creatorcontrib>Netea, M. G.</creatorcontrib><creatorcontrib>Tack, C. J.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes, obesity &amp; metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Poppel, P. C. M.</au><au>van Asseldonk, E. J. P.</au><au>Holst, J. J.</au><au>Vilsbøll, T.</au><au>Netea, M. G.</au><au>Tack, C. J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance</atitle><jtitle>Diabetes, obesity &amp; metabolism</jtitle><addtitle>Diabetes Obes Metab</addtitle><date>2014-12</date><risdate>2014</risdate><volume>16</volume><issue>12</issue><spage>1269</spage><epage>1273</epage><pages>1269-1273</pages><issn>1462-8902</issn><eissn>1463-1326</eissn><coden>DOMEF6</coden><abstract>Inflammation at the level of the β cell appears to be involved in progressive β‐cell dysfunction in type 2 diabetes. We assessed the effect of blocking interleukin‐1 (IL‐1) by anakinra [recombinant human interleukin‐1 receptor antagonist (IL‐1Ra)] on β‐cell function. Sixteen participants with impaired glucose tolerance were treated with 150 mg anakinra daily for 4 weeks in a double blind, randomized, placebo‐controlled cross‐over study with a wash‐out period of 4 weeks. At the end of each treatment period, oral glucose tolerance tests (OGTTs) and hyperglycaemic clamps were performed. First‐phase insulin secretion improved after anakinra treatment compared with placebo, 148 ± 20 versus 123 ± 14 mU/l, respectively (p = 0.03), and the insulinogenic index was higher after anakinra treatment. These results support the concept of involvement of IL‐1β in the (progressive) decrease of insulin secretion capacity associated with type 2 diabetes.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>25039318</pmid><doi>10.1111/dom.12357</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1462-8902
ispartof Diabetes, obesity & metabolism, 2014-12, Vol.16 (12), p.1269-1273
issn 1462-8902
1463-1326
language eng
recordid cdi_proquest_miscellaneous_1654684713
source Wiley-Blackwell Read & Publish Collection
subjects Beta cells
Blood Glucose - drug effects
Cross-Over Studies
Diabetes
diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - drug therapy
Double-Blind Method
drug mechanism
experimental pharmacology
Female
Glucose Intolerance - blood
Glucose Intolerance - drug therapy
Glucose tolerance
Glucose Tolerance Test
Humans
Hypoglycemic Agents - administration & dosage
Hypoglycemic Agents - therapeutic use
Insulin - metabolism
Insulin Secretion
Insulin-Secreting Cells - drug effects
Insulin-Secreting Cells - metabolism
Interleukin 1 receptor antagonist
Interleukin 1 Receptor Antagonist Protein - administration & dosage
Interleukin 1 Receptor Antagonist Protein - therapeutic use
Male
Middle Aged
Placebos
Receptors, Interleukin-1 - antagonists & inhibitors
Treatment Outcome
type 2 diabetes
β cell
title The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T05%3A53%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20interleukin-1%20receptor%20antagonist%20anakinra%20improves%20first-phase%20insulin%20secretion%20and%20insulinogenic%20index%20in%20subjects%20with%20impaired%20glucose%20tolerance&rft.jtitle=Diabetes,%20obesity%20&%20metabolism&rft.au=van%20Poppel,%20P.%20C.%20M.&rft.date=2014-12&rft.volume=16&rft.issue=12&rft.spage=1269&rft.epage=1273&rft.pages=1269-1273&rft.issn=1462-8902&rft.eissn=1463-1326&rft.coden=DOMEF6&rft_id=info:doi/10.1111/dom.12357&rft_dat=%3Cproquest_cross%3E1622596927%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5227-7f7fff23e344df86c01dfc0a5782ff6b1c8c9e28b425270994411e2ab08c48fa3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1622020570&rft_id=info:pmid/25039318&rfr_iscdi=true